MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group

被引：1

作者：

O'Connor, P ^{[1
]}

Fleming, P ^{[1
]}

Gray, T ^{[1
]}

Jacobs, L ^{[1
]}

Miller, C ^{[1
]}

Munschauer, F ^{[1
]}

Kinkel, RP ^{[1
]}

Bolibrush, D ^{[1
]}

Cohen, J ^{[1
]}

Freedman, M ^{[1
]}

Webb, U ^{[1
]}

Rabinowicz, H ^{[1
]}

Metz, LM ^{[1
]}

Patry, D ^{[1
]}

Yeung, M ^{[1
]}

Peters, S ^{[1
]}

Hashimoto, S ^{[1
]}

Morrison, W ^{[1
]}

Oger, J ^{[1
]}

Panitch, H ^{[1
]}

Costello, K ^{[1
]}

Bever, C ^{[1
]}

Stuart, W ^{[1
]}

Court, D ^{[1
]}

Stuart, D ^{[1
]}

Tornatore, C ^{[1
]}

Bartlett, D ^{[1
]}

Richert, J ^{[1
]}

Duquette, P ^{[1
]}

Dubois, R ^{[1
]}

Bernier, G ^{[1
]}

Scott, T ^{[1
]}

Pappert, L ^{[1
]}

Brillman, J ^{[1
]}

Felton, W ^{[1
]}

Anderson, T ^{[1
]}

Astruc, J ^{[1
]}

Rose, J ^{[1
]}

Kline, J ^{[1
]}

Burns, J ^{[1
]}

Murray, T ^{[1
]}

Weldon, P ^{[1
]}

Bhan, V ^{[1
]}

Maxner, CE ^{[1
]}

Wall, M ^{[1
]}

Vining, L ^{[1
]}

Grabowski, T ^{[1
]}

Apatoff, B ^{[1
]}

Orapello, C ^{[1
]}

Friedman, J ^{[1
]}

机构：

[1] Univ Colorado, Hlth Sci Ctr, Dept Radiol, Denver, CO 80262 USA

来源：

NEUROLOGY | 2002年 / 59卷 / 07期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Objective: To assess the ability of baseline MRI characteristics to predict the early development of clinically definite MS (CDMS) and combined CDMS/MRI outcomes in 190 patients with a positive MRI at the time of their first demyelinating event. Methods: Based on individual and sets of baseline MRI characteristics, the authors evaluated the percentage of patients meeting outcomes of CDMS and various combined CDMS/MRI outcomes by 18 months. They also optimized a cutpoint for dichotomizing each baseline MRI characteristic and evaluated these variables using logistic regression to determine which MRI characteristics best predicted CDMS by 18 months. Results: The presence of two or more gadolinium-enhancing lesions better predicted the development of CDMS and combined CDMS/MRI outcomes by 18 months than any other individual MRI characteristic or set of MRI characteristics. Among patients with two or more gadolinium-enhancing lesions, 52% developed CDMS compared with 24% of patients with fewer than two lesions. For those meeting the criteria of Barkhof et al., 32% of patients developed CDMS compared with 16% of those not meeting these criteria. Irrespective of individual or sets of criteria, however, the majority of patients developed either CDMS or demonstrated disease activity on brain MRI by 18 months. Conclusions: For patients with positive MRI at the time of their initial neurologic event, both gadolinium-enhancing lesions and the Barkhof criteria are predictors for development of CDMS over a short interval. However, these results, based on a combined CDMS/MRI outcome, suggest that the majority of these patients are already in the earliest stages of MS, regardless of whether any further MRI criteria are met.

引用

页码：998 / 1005

页数：8

共 50 条

[31] Combined omics analysis of cerebrospinal fluid is able to predict conversion from clinically isolated syndrome to clinically definite MS within 4 years
Probert, F.
Yeo, T.
Sealey, M.
Palace, J.
Leppert, D.
Kuhle, J.
Anthony, D. C.
MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 277 - 278
[32] Predictors of short-term disease activity following a first clinical demyelinating event: analysis of the CHAMPS placebo group
O'Connor, P
Fleming, P
Gray, T
Jacobs, L
Miller, C
Munschaner, F
Kinkel, RP
Bolibrush, D
Cohen, J
Freedman, M
Webb, U
Rabinowicz, H
Metz, LM
Patry, D
Yeung, M
Peters, S
Hashimoto, S
Morrison, W
Oger, J
Panitch, H
Costello, K
Bever, C
Stuart, W
Court, D
Stuart, D
Tornatore, C
Bartlett, D
Richert, J
Duquette, P
Dubois, R
Bernier, G
Scott, T
Pappert, L
Brillman, J
Felton, W
Anderson, T
Astruc, J
Rose, J
Kline, J
Burns, J
Murray, T
Weldon, P
Bhan, V
Maxner, CE
Wall, M
Vining, L
Grabowski, T
Apatoff, B
Orapello, C
Friedman, J
MULTIPLE SCLEROSIS JOURNAL, 2002, 8 (05) : 405 - 409
[33] THE EFFECT OF CLADRIBINE TABLETS ON DELAYING THE TIME TO CONVERSION TO CLINICALLY DEFINITE MULTIPLE SCLEROSIS (MS) OR MCDONALD MS IS CONSISTENT ACROSS SUBGROUPS IN THE ORACLE-MS STUDY
Bowen, James
Gillett, Alan
Damian, Doris
Hyvert, Yann
Dangond, Fernando
Grosso, Megan
Leist, Thomas
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2019, 90 (E7):
[34] Increased expression of Tbet in CD4+ T cells from clinically isolated syndrome patients at high risk of conversion to clinically definite MS
Basdeo, Sharee A.
Kelly, Siobhan
O'Connell, Karen
Tubridy, Niall
McGuigan, Christopher
Fletcher, Jean M.
SPRINGERPLUS, 2016, 5
[35] Acute partial transverse myelitis with normal brain MRI: Conversion to clinically definite multiple sclerosis after five years
Khan, O
Caon, C
Tselis, A
Zabad, R
Reznar, M
Lisak, R
NEUROLOGY, 2005, 64 (06) : A238 - A239
[36] gMS-Classifier2 serum assay as a potential predictor of early conversion to clinically definite multiple sclerosis in patients with clinically isolated syndromes
Arrambide, G.
Espejo, C.
Yarden, J.
Fire, E.
Spector, L.
Dotan, N.
Rovira, A.
Montalbn, X.
Tintore, M.
MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S498 - S498
[37] Brain MRI correlates of cognitive function in early treated MS and clinically isolated syndrome
Cohen, M.
Joly, H.
Brochet, B.
Clavelou, P.
Lepage, E.
Vermersch, P.
Lebrun, C.
MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 325 - 325
[38] Non-lesional cerebellar damage in patients with clinically isolated syndrome: DTI measures predict early conversion into clinically definite multiple sclerosis
Kugler, Alexa, V
Deppe, Michael
NEUROIMAGE-CLINICAL, 2018, 19 : 633 - 639
[39] Correlation between MRI Measures and Conversion to Clinically Definite Multiple Sclerosis in Patients Treated with Intramuscular Interferon Beta-1a
Horakova, Dana
Kalincik, Tomas
Tyblova, Michaela
Krasensky, Jan
Vaneckova, Manuela
Seidl, Zdenek
You, Xiaojun
Havrdova, Eva
NEUROLOGY, 2012, 78
[40] Cerebrospinal fluid/serum CXCL13 ratio: an early prognostic marker of conversion to clinically definite multiple sclerosis
Dujmovic, I.
Gredler, V.
Schanda, K.
Mesaros, S.
Dackovic, J.
Vitas, J.
Pekmezovic, T.
Deisenhammer, F.
Berger, T.
Drulovic, J.
Reindl, M.
MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 357 - 358

← 1 2 3 4 5 →